# A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

> **NCT03981627** · PHASE1,PHASE2 · COMPLETED · sponsor: **Adocia** · enrollment: 44 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** ADO09 formulation
- **DRUG:** NovoRapid®

## Key facts

- **NCT ID:** NCT03981627
- **Lead sponsor:** Adocia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-06
- **Primary completion:** 2020-06-27
- **Final completion:** 2020-06-27
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981627, "A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03981627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*